Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease

Soluble CD163 is associated with noninvasive measures of liver fibrosis in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected women

(2015) Mark H. Kuniholm et al.   HEPATOLOGY

Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery

(2015) Konstantin Kazankov et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Macrophage Inflammatory Markers Are Associated With Subclinical Carotid Artery Disease in Women With Human Immunodeficiency Virus or Hepatitis C Virus Infection

(2014) Iftach Shaked et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C

(2014) Konstantin Kazankov et al.   HEPATOLOGY

Plasma sCD14 as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis

(2014) Bradley S. Quon et al.   PLoS One

Reduced sTWEAK and Increased sCD163 Levels in HIV-Infected Patients: Modulation by Antiretroviral Treatment, HIV Replication and HCV Co-Infection

(2014) Luis M. Beltrán et al.   PLoS One

Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study

(2013) E. S. Andersen et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Hepatic macrophage activation predicts clinical decompensation in chronic liver disease

(2013) Anthony Rode et al.   GUT

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

(2013) Kenneth Cusi et al.   JOURNAL OF HEPATOLOGY

The Macrophage-Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss

(2013) Karen Fjeldborg et al.   Obesity

Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis

(2012) H. Grønbaek et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling

(2012) Kento Imajo et al.   Cell Metabolism

NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications

(2012) Geoffrey C. Farrell et al.   Gut and Liver

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients

(2012) Pierre Bedossa et al.   HEPATOLOGY

Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects

(2011) Markella V. Zanni et al.   CLINICAL ENDOCRINOLOGY

Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection

(2011) Netanya G. Sandler et al.   GASTROENTEROLOGY

Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS

(2011) P. Holland-Fischer et al.   GUT

Endpoints and clinical trial design for nonalcoholic steatohepatitis

(2011) Arun J. Sanyal et al.   HEPATOLOGY

Soluble CD163, a Novel Marker of Activated Macrophages, Is Elevated and Associated With Noncalcified Coronary Plaque in HIV-Infected Patients

(2011) Tricia H. Burdo et al.   JOURNAL OF INFECTIOUS DISEASES

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective

(2008) Mariana Lazo et al.   SEMINARS IN LIVER DISEASE